Skip to content
TrialScanner

NCT04107142

Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour

Phase 1Unknown statusGDTCLead

Registry record

Lead sponsor
CytoMed Therapeutics Pte Ltd
Conditions
Colorectal Cancer; Triple Negative Breast Cancer; Sarcoma; Nasopharyngeal Carcinoma; Prostate Cancer
Primary completion
Sep 1, 2020Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT04107142 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04107142: Haplo / Allogeneic NKG2DL-tar... | TrialScanner